Patents Assigned to AstraZeneca
  • Process for the preparation of esomeprazole non-salt form
    Patent number: 8124779
    Abstract: The present invention relates to a new process for the preparation of new crystal modifications of esomeprazole non-salt form. Further, the present invention also relates to the use of said new crystal modifications for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as the crystal modifications, as such.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: February 28, 2012
    Assignee: AstraZeneca AB
    Inventors: Martin Bohlin, Per Lindberg
  • MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES
    Publication number: 20120046219
    Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.
    Type: Application
    Filed: October 26, 2011
    Publication date: February 23, 2012
    Applicant: AstraZeneca AB
    Inventors: John H. DODD, Yi-Qun Shi, Wei Yang
  • Piperidine derivatives and their use as muscarinic receptor modulators
    Patent number: 8119661
    Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R2, R3, X, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: February 21, 2012
    Assignee: AstraZeneca AB
    Inventors: Yun-Xing Cheng, Xuehong Luo, Vijayaratnam Santhakumar, Miroslaw Jerzy Tomaszewski
  • Compounds 148
    Patent number: 8119673
    Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: February 21, 2012
    Assignee: AstraZeneca AB
    Inventors: Jonas Brånalt, David Gustafsson, Ingemar Nilsson, Magnus Polla
  • Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
    Patent number: 8114435
    Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Helene Depui, Per Lundberg
  • 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
    Patent number: 8114881
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
    Patent number: 8114989
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Bin Wang, Tao Wang
  • CHEMICAL COMPOUNDS
    Publication number: 20120035134
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 9, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Robert Bruce DIEBOLD, Thomas GERO, Paul GROVER, Shan HUANG, Stephanos IOANNIDIS, Claude Afona OGOE, Jamal Carlos SAEH, Jeffrey Gilbert VARNES
  • 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE
    Publication number: 20120035157
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: AstraZeneca AB
    Inventors: Marjana Andersson, Peter Hansen, Hans Lönn, Antonios Nikitidis, Petter Sjölin
  • Compound for the Treatment of Tuberculosis
    Publication number: 20120035219
    Abstract: (5R)-3-[4-[1-[(2S)-2,3-dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5-difluoro-phenyl]-5-(isoxazol-3-yloxymethyl)oxazolidin-2-one, or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, for use in the treatment of Mycobacterium tuberculosis.
    Type: Application
    Filed: March 16, 2010
    Publication date: February 9, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Kaveri Das, David Alan Melnick, Shandil Radha
  • CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-...
    Publication number: 20120035363
    Abstract: 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: ASTRAZENECA AB
    Inventor: Andrew Hornby Dobson
  • Therapeutic agents 713
    Patent number: 8110566
    Abstract: Disclosed herein are compounds of formula I in which R1, R2, R3, R4, R5, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: February 7, 2012
    Assignee: AstraZeneca AB
    Inventors: Lars Anders Mikael Johansson, Robert Andrew Judkins, Lanna Li, Bjorn Christian Ingvar Lofberg, Joachim Persson
  • CHEMICAL COMPOUNDS
    Publication number: 20120028924
    Abstract: The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.
    Type: Application
    Filed: August 2, 2011
    Publication date: February 2, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Brian AQUILA, Victor KAMHI, Bo PENG, Timothy PONTZ, Jamal Carlos SAEH, Kumar THAKUR, Bin YANG
  • Quinoline derivatives 057
    Patent number: 8106073
    Abstract: The invention provides a compound of formula (I) as defined in the specification, a process for its preparation, pharmaceutical compositions containing it, a process for preparing the pharmaceutical composition, and its use in therapy.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: January 31, 2012
    Assignee: AstraZeneca AB
    Inventors: Simon David Guile, Toby Thompson
  • Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
    Patent number: 8106063
    Abstract: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: January 31, 2012
    Assignee: AstraZeneca AB
    Inventors: Mark Ebden, Premji Meghani, Colin Bennion, Anthony Ronald Cook, Roger Victor Bonnert
  • PHARMACEUTICAL DEPOT FOR 5-FLUORO-2-[[(1S)-1-(5-FLUORO-2-PYRIDYL)ETHYL]AMINO]-6-[(5-ISOPROPOXY-1H-PYRAZOL-3-YL)AMINO]PYRIDINE-3-CARBONITRILE
    Publication number: 20120022110
    Abstract: A pharmaceutical depot comprising (i) 5-fluoro-2-[[(1S)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.
    Type: Application
    Filed: July 19, 2011
    Publication date: January 26, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Armelle Marie-Laudine JANIN, Philip Alexander MACFAUL, Rachel Marie PUGH, Emily Jane ROBERTS, Ian Alun NASH
  • 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS
    Publication number: 20120022107
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: December 11, 2009
    Publication date: January 26, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Shahul Hameed Peer Mohamed, David Waterson
  • PYRAZINE DERIVATIVES
    Publication number: 20120022082
    Abstract: The invention concerns pyrazine derivatives of the Formula I or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions.
    Type: Application
    Filed: January 18, 2011
    Publication date: January 26, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Tao FENG, Hitesh Jayantilal SANGANEE, Hiroki WADA
  • Process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-indole-5-carbonitrile 701
    Patent number: 8101750
    Abstract: The present invention relates to a new process for the manufacture of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base and pharmaceutically acceptable salts thereof, particularly the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, and to new intermediates prepared in said process suitable for large scale manufacturing of said compound.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: January 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Vern Delisser, Martin Hedberg, Annette Jansson, Andreas Rådevik, Per Ryberg, Swantje Thiering
  • Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
    Patent number: 8101623
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I), methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: January 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Richard William Arthur Luke, Zbigniew Stanley Matusiak